Welcome to Trends-in-Medicine, offering independent, cutting-edge articles and information on drugs and devices in development. Our subscribers have access to news and analysis on the latest data, regulatory issues, and trends of interest to the healthcare community.

Quick Takes for April 21, 2024

American Academy of Neurology

Among the interesting data on new drugs (and new uses for existing drugs) at AAN were treatments for Angelman syndrome, chronic infectious demyelinating polyneuropathy (CIDP), Devic disease (NMOSD), Huntington's disease (HD), migraine, multiple sclerosis.

FDA Oncology Drugs Advisory Committee (ODAC) Update

This is a must read for anyone interested in ODAC because changes are coming: In-person meetings will resume, less emphass on industry “outside experts,” a new style for briefing documents, encouragement for more “pragmatic” trials. Two things that won't change: panels will continue to vote, and drug prices will continue to be left out of discussions.

American Academy of Dermatology

Drug development is alive and well in dermatology, and among the interesting data at AAD were studies on new drugs/new uses for existing drugs -- and a botanical -- for psoriasis, submental fat, hidradenitis suppurativa (HS), atopic dermatitis, and alopecia

Alzheimer's Update

The data on Eisai and Biogen’s Leqembi (lecanemab) was the highlight of the Clinical Trials on Alzheimer's Disease (CTAD) meeting in Boston. Here we dive into the data.